Coherus Oncology (CHRS) Cost of Revenue (2019 - 2026)

Coherus Oncology has disclosed Cost of Revenue across 8 years of filings, most recently posting $3.8 million for Q1 2026.

• Cost of Revenue for Q1 2026 came in at $3.8 million, up 43.76% year-over-year; the trailing twelve-month figure through Mar 2026 was $15.0 million (up 50.64% YoY), and the FY2025 annual result was $13.8 million, up 58.29% from the prior year.
• Cost of Revenue came in at $3.8 million for Q1 2026 at Coherus Oncology, down from $4.0 million in the prior quarter.
• In the past five years, Cost of Revenue ranged from a high of $84.6 million in Q4 2023 to a low of $1.4 million in Q1 2024.
• The 5-year median for Cost of Revenue is $4.0 million (2025), against an average of $15.0 million.
• Across the five-year window, Cost of Revenue surged 495.46% in 2023 and sank 96.75% in 2024, its largest moves.
• Coherus Oncology's Cost of Revenue stood at $14.2 million in 2022, then soared by 495.46% to $84.6 million in 2023, then tumbled by 96.75% to $2.8 million in 2024, then jumped by 47.09% to $4.0 million in 2025, then declined by 5.71% to $3.8 million in 2026.
• The last three Cost of Revenue figures came in at $3.8 million (Q1 2026), $4.0 million (Q4 2025), and $3.7 million (Q3 2025), per Business Quant data.